U.S. Markets open in 6 hrs 51 mins

Holding(s) in Company


Holding(s) in Company

December 28, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG)

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: Shire Plc
JE00B2QKY057
1b. Please indicate if the issuer is a non-UK issuer  (please mark with an “X” if appropriate)
Non-UK issuer X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments  
An event changing the breakdown of voting rights  
Other (please specify)iii:  
3. Details of person subject to the notification obligationiv
Name UBS Investment Bank
UBS Group AG
City and country of registered office (if applicable) Zürich
Switzerland
4. Full name of shareholder(s) (if different from 3.)v
Name UBS AG London Branch
City and country of registered office (if applicable) London, United Kingdom
5. Date on which the threshold was crossed or reachedvi: 21 December 2018
6. Date on which issuer notified (DD/MM/YYYY): 27 December 2018
7. Total positions of person(s) subject to the notification obligation
  % of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B) Total number of voting rights of issuervii
Resulting situation on the date on which threshold was crossed or reached 6.68 % 2.24 % 8.92 % 917,454,601  
Position of previous notification (if
applicable)
3.55 % 2.25 % 5.80 %  

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type of
shares

ISIN code (if possible)
Number of voting rightsix % of voting rights
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
JE00B2QKY057   61'306'023   6.68 %
         
         
SUBTOTAL 8. A 61'306'023 6.68 %
 

 
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument Expiration
date
x
Exercise/
Conversion Period
xi
Number of voting rights that may be acquired if the instrument is
exercised/converted.
% of voting rights
Right to recall lent ADRs (US82481R1068)   Anytime 1'775'070 0.19 %
US82481R1068     17'190'369 1.87 %
Physically settled Long Call Options 18/01/2019 to 18/04/2019   933'000 0.10 %
    SUBTOTAL 8. B 1 19'898'439 2.17 %
 

 
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument Expiration
date
x
Exercise/
Conversion Period
xi
Physical or cash
settlementxii
Number of voting rights % of voting rights
Short Put  Options 18/01/2019   Physical 658'800 0.07 %
           
           
      SUBTOTAL 8.B.2 658'800 0.07 %
 


9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii  
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)
X
Namexv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
UBS Group AG      
UBS AG      
UBS AG London Branch 6.67 %   8.91 %
       
UBS Group AG      
UBS AG      
UBS Limited      
       
UBS Group AG      
UBS AG      
UBS Switzerland AG      
       
UBS Group AG      
UBS AG      
UBS Americas Holding LLC      
UBS Americas Inc.      
UBS Securities LLC      


 
10. In case of proxy voting, please identify:
Name of the proxy holder  
The number and % of voting rights held  
The date until which the voting rights will be held  
 
11. Additional informationxvi
 


Place of completion Opfikon, Switzerland
Date of completion 27.12.2018

For further information please contact:

Investor Relations    
Christoph Brackmann christoph.brackmann@shire.com +41 41 288 41 29
Sun Kim sun.kim@shire.com +1 617 588 8175
Scott Burrows scott.burrows@shire.com +41 41 288 4195
     
Media    
Katie Joyce kjoyce@shire.com  +1 781 482 2779
     

NOTES TO EDITORS

About Shire

Shire is the global biotechnology leader serving patients with rare diseases and specialized conditions. We seek to push boundaries through discovering and delivering new possibilities for patient communities who often have few or no other champions. Relentlessly on the edge of what’s next, we are serial innovators with a diverse pipeline offering fresh thinking and new hope. Serving patients and partnering with healthcare communities in over 100 countries, we strive to be part of the entire patient journey to enable earlier diagnosis, raise standards of care, accelerate access to treatment, and support patients. Our diverse portfolio of therapeutic areas includes Immunology, Hematology, Genetic Diseases, Neuroscience, Internal Medicine, and Ophthalmics.
 
Championing patients is our call to action - it brings the opportunity - and responsibility - to change people’s lives.

www.shire.com